Johnson & Johnson, “effective vaccine on Delta variant”

Johnson & Johnson, Janssen’s single-dose Covid vaccine “demonstrated a durable immune response and generated neutralizing antibody responses against the Delta variant and other Sars-CoV-2 variants of concern.” This was reported by J&J, communicating the interim results of a phase 1 / 2a substudy published in the ‘New England Journal of Medicine’ (Nejm).

“Antibody and T-cell immune responses were observed for at least 8 months after immunization,” reports the US pharmaceutical group. Furthermore, “neutralizing antibody activity against the Delta variant (B.1.617.2) has been shown to increase over time”. J&J announced the results of this substudy in a pre-publication on July 1st.

!function(f,b,e,v,n,t,s)
{if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};
if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version=’2.0′;
n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];
s.parentNode.insertBefore(t,s)}(window, document,’script’,
‘https://connect.facebook.net/en_US/fbevents.js’);
fbq(‘init’, ‘415374439673532’);
fbq(‘track’, ‘PageView’);